Know Cancer

or
forgot password

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study


N/A
17 Years
90 Years
Not Enrolling
Both
Malignant Lymphoma, P13K-AKT Pathway Deregulation

Thank you

Trial Information

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study


Recently, among diverse oncogenic signaling pathways, a number of studies have focused on
the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine
kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol
3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and
plays a critical role promoting malignant phenotype and has prognostic significance in
various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes
has not been performed in malignant lymphoma.


Inclusion Criteria:



1. the patients were pathologically confirmed of malignant lymphoma, according to the
World Health Organization classification;

2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for
immunostaining of p-AKT.

Exclusion Criteria:

1. Primary central nervous system lymphoma was excluded in this study

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Difference of overall survival according to p-AKT status in malignant lymphoma

Outcome Time Frame:

study entry

Safety Issue:

No

Principal Investigator

Won Seog Kim, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Samsung Medical Center

Authority:

South Korea: Institutional Review Board

Study ID:

2013-01-047

NCT ID:

NCT01789060

Start Date:

December 2012

Completion Date:

February 2013

Related Keywords:

  • Malignant Lymphoma
  • P13K-AKT Pathway Deregulation
  • Lymphoma

Name

Location